SYMBIOTYC® provides its customers with more than 20 years of experience in the healthcare industry. It helps pharmaceutical, medical... View Article
Author Archives for Adeline Chauvigné
New member | SYMBIOTYC
14 May 2025SYMBIOTYC® provides its customers with more than 20 years of experience in the healthcare industry. It helps pharmaceutical, medical... View Article
KetoM+ | The first product developed
FACILITATING ACCESS TO METABOLIC THERAPEUTIC DIET, HAS DEVELOPED ITS 1ST PRODUCT: A SPECIFIC GROUP FOOD (SGA). It is a formula... View Article
KetoM+ | The first product developed
14 May 2025FACILITATING ACCESS TO METABOLIC THERAPEUTIC DIET, HAS DEVELOPED ITS 1ST PRODUCT: A SPECIFIC GROUP FOOD (SGA). It is a formula... View Article
Launch of a healthcare science and innovation partnership between Philips and Rennes University Hopistal that is unique in France
To mark the launch of their science and innovation partnership, Rennes CHU and Philips have spotlighted three major focus... View Article
Launch of a healthcare science and innovation partnership between Philips and Rennes University Hopistal that is unique in France
14 May 2025To mark the launch of their science and innovation partnership, Rennes CHU and Philips have spotlighted three major focus... View Article
New member | IRICE
Jeanne Chamousset-Roman is Consultant in Regulatory Affairs and Quality Management in MEDICAL DEVICES supporting companies for various procedures: Regulatory... View Article
New member | IRICE
14 May 2025Jeanne Chamousset-Roman is Consultant in Regulatory Affairs and Quality Management in MEDICAL DEVICES supporting companies for various procedures: Regulatory... View Article
Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
Valneva, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it is... View Article
Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
14 May 2025Valneva, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it is... View Article
Valneva Reports FY 2020 Cash of Over €200 Million
FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million. FY 2020... View Article
Valneva Reports FY 2020 Cash of Over €200 Million
14 May 2025FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million. FY 2020... View Article
New member | MAD-UP
MAD-UP specializes in the development of technological solutions for the health care of musculoskeletal disorders. Its intelligent dynamic compression solution... View Article
New member | MAD-UP
14 May 2025MAD-UP specializes in the development of technological solutions for the health care of musculoskeletal disorders. Its intelligent dynamic compression solution... View Article
GlioCure announces that it has been granted patent protection of its drug candidate GC01 in India
GlioCure SAS, a biotechnology company specialised in neuro-oncology, announced that it has been granted an Indian patent for its drug... View Article
GlioCure announces that it has been granted patent protection of its drug candidate GC01 in India
14 May 2025GlioCure SAS, a biotechnology company specialised in neuro-oncology, announced that it has been granted an Indian patent for its drug... View Article
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
OSE Immunotherapeutics today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the benefits of anti-IL-7... View Article
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
14 May 2025OSE Immunotherapeutics today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the benefits of anti-IL-7... View Article
OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine
• CoVepiT demonstrated generation of sentinel memory T cells with long-term protective effect against COVID-19 in preclinical and human ex... View Article
OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine
14 May 2025• CoVepiT demonstrated generation of sentinel memory T cells with long-term protective effect against COVID-19 in preclinical and human ex... View Article